Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sargramostim + ipilimumab
- Development stage
- Unknown
- Lead developer
- Partner Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Sargramostim + ipilimumab is a combination therapy used primarily in advanced melanoma. Sargramostim is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). It enhances antigen presentation and boosts antitumor activity through stimulation of dendritic cells and T/B lymphocytes. Ipilimumab is a fully human IgG1 monoclonal antibody targeting cytotoxic T lymphocyte antigen-4 (CTLA-4), increasing immune-mediated attack against tumor cells. In clinical studies, this combination improved overall survival and reduced high-grade immune-related adverse events compared to ipilimumab alone. Its mechanism integrates immune checkpoint blockade with cytokine-mediated enhancement of immune response[1][2][3][4][5].
- Brand names
- Leukine + Yervoy
- Other names
- GM-CSF + ipilimumabGranulocyte-macrophage colony-stimulating factor + ipilimumab
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)
Beyond the preview
Go deeper on sargramostim + ipilimumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sargramostim + ipilimumab.